=>
Uploading C:\Program Files\Stnexp\Queries\10571279.str



chain nodes :
8 9 10 11 12 22 23
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 19 20 21
chain bonds :
4-8 6-9 9-10 9-11 9-12 12-13 16-23 19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 17-19 18-21
19-20 20-21
exact/norm bonds :
4-8 6-9 9-10 9-11 9-12 12-13 16-23 17-18 17-19 18-21 19-20 19-22 20-21

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17
isolated ring systems :
containing 1 : 13 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:CLASS
23:CLASS

L1 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 22:50:56 ON 17 MAR 2008
L1 STRUCTURE UPLOADED

L3 2 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 22:51:21 ON 17 MAR 2008
L4 20 S L3
L5 2 S US200!-5712?9/APPS
L6 1 S L4 AND L5
L7 19 S L4 NOT L5

FILE 'REGISTRY' ENTERED AT 22:52:00 ON 17 MAR 2008

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:260023 CAPLUS <<LOGINID::20080317>>
DN 142:341835
TI Preparation of crystals of N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide
IN Takahashi, Keiko; Hayashi, Kenji; Abe, Taichi; Omae, Takao; Kato, Takashi
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026118	A1	20050324	WO 2004-JP12649	20040901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004272400	A1	20050324	AU 2004-272400	20040901
	CA 2536995	A1	20050324	CA 2004-2536995	20040901
	EP 1666463	A1	20060607	EP 2004-772605	20040901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1849305	A	20061018	CN 2004-80026069	20040901
	BR 2004014314	A	20061031	BR 2004-14314	20040901
	MX 2006PA02732	A	20060605	MX 2006-PA2732	20060309
	NO 2006001545	A	20060609	NO 2006-1545	20060405
	IN 2006CN01232	A	20070810	IN 2006-CN1232	20060407
	US 2007082941	A1	20070412	US 2006-571279	20061226 <--
PRAI	JP 2003-318953	A	20030910		
	WO 2004-JP12649	W	20040901		

AB Claimed are the title crystals. The title compound is an antitumor agent (no data). When examined by X-ray powder diffractometry, the above crystals have a diffraction peak at the diffraction angle (2θ.+-.0.2°)19.1°. Crystals of this invention showed high

photostability. Formulations containing crystals of this invention are given.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l7 tot bib abs hitstr

L7 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1237479 CAPLUS <<LOGINID::20080317>>
DN 147:462224
TI Novel marker for sensitivity against sulfonamide compound
IN Semba, Taro
PA Eisai R & D Management Co., Ltd., Japan
SO PCT Int. Appl., 82pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007123274	A1	20071101	WO 2007-JP59139	20070420
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2006-117183	A	20060420		

OS MARPAT 147:462224
AB The sensitivity of a tumor cell against a sulfonamide compound or the anti-tumor effect of a sulfonamide compound in a tumor cell can be examined by determining the expression level of EGFR1 in the tumor cell and employing the variation in the EGFR1 expression level as a measure. Thus, disclosed are: a method for determination of the sensitivity of a tumor cell against a sulfonamide compound; a method for determination of the anti-tumor effect of a sulfonamide compound; and a detection kit for use in these methods.
IT 289483-69-8, E7820
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EGFR1 as novel marker for antitumor sensitivity of sulfonamide compds.)
RN 289483-69-8 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:845823 CAPLUS <<LOGINID::20080317>>
DN 147:203891
TI Method for prediction of the effect of sulfonamide compound
IN Ozawa, Yoichi
PA Eisai R & D Management Co., Ltd., Japan
SO PCT Int. Appl., 57pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007086605	A1	20070802	WO 2007-JP51747	20070126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2006-18912	A	20060127		

AB Disclosed is a method for prediction of the anti-tumor effect of a sulfonamide compound The anti-tumor effect of a sulfonamide compound can be predicted by measuring the amount of neuron-specific enolase and determining the anti-tumor effect based on the amount of neuron-specific enolase.
IT 289483-69-8, E 7820
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for prediction of the effect of sulfonamide compds. as antitumor agents by measuring the amount of neuron-specific enolase)
RN 289483-69-8 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1217188 CAPLUS <<LOGINID::20080317>>
DN 146:134591
TI Chemistry and biology of a series of antitumor sulfonamides: exploiting transcriptomic and quantitative proteomic analyses for exploring drug gable chemical space
AU Owa, Takashi
CS Discovery Res. Lab. II, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan
SO Yuki Gosei Kagaku Kyokaishi (2006), 64(11), 1171-1179
CODEN: YGKKAE; ISSN: 0037-9980
PB Yuki Gosei Kagaku Kyokai
DT Journal
LA English
AB Sulfolnamide-focused compound libraries have been synthesized in our labs. for biol. evaluation using antitumor phenotypic screens such as cancer cell proliferation assay, flow cytometric cell cycle anal., and rat aorta tube formation assay. Among thousands of sulfonamide compds. evaluated, E7010 (a microtubule depolymg. agent), E7070 (a G1 phase cell cycle inhibitor), and E7820 (an antiangiogenesis agent) have progressed to clin. trials, thereby demonstrating some objective responses in cancer patients so far. The sequential discovery of these drug candidates allowed us to carry out a research approach of forward chemical genetics, in which phenotypically bioactive compds. are selected from a large collection of small mols. and then utilized for understanding the functions of their protein partners and relevant biol. pathways via target identification. This paper describes our attempt using oligonucleotide microarray and quant. proteomic analyses not only for identifying drug targets and downstream pathways applicable to biomarkers but also for exploring drug gable chemical space in medicinal chemical research.
IT 289483-69-8P, E7820
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Chemical and biol. of a series of antitumor sulfonamides: exploiting transcriptomic and quant. proteomic analyses for exploring drug gable chemical space)
RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:88397 CAPLUS <<LOGINID::20080317>>
DN 145:263277
TI Novel combinational use of sulfonamide compound
IN Owa, Takashi; Ozawa, Yoichi; Semba, Taro; Wakabayashi, Toshiaki
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 128pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006090930	A1	20060831	WO 2006-JP304218	20060228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006217692	A1	20060831	AU 2006-217692	20060228
	CA 2599115	A1	20060831	CA 2006-2599115	20060228
	EP 1859793	A1	20071128	EP 2006-715261	20060228
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	KR 2007108270	A	20071108	KR 2007-722300	20070928
PRAI	JP 2005-54111	A	20050228		
	WO 2006-JP304218	W	20060228		

OS MARPAT 145:263277

AB Disclosed is a pharmaceutical composition, a kit and a method for the treatment of cancer which are characterized in that a sulfonamide compound is used in combination with a substance having an EGF inhibitory activity. For example, the synergic antitumor effect of combination of E7820 and gefitinib was examined in vitro.

IT 289483-69-8, E 7820
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel combinational use of sulfonamide compds. with EGF-inhibitors)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:888376 CAPLUS <<LOGINID::20080317>>

DN 145:285081

TI Surrogate marker for sulfonamide compound

IN Owa, Takashi; Ozawa, Yoichi; Ono, Naoto

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 54pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006090932	A1	20060831	WO 2006-JP304221	20060228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

EP 1797877 A1 20070620 EP 2005-785820 20050913
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
PRAI JP 2005-54475 A 20050228
US 2004-609452P P 20040913
JP 2005-54150 A 20050228
WO 2005-JP17238 W 20050913
OS MARPAT 145:285081
AB A method of evaluating the effect of a sulfonamide compound on the expression of integrin which involves: (a) the step of measuring the expression amount of integrin in platelets collected from a patient to whom the above-described sulfonamide compound has been administered; and (b) the step of evaluating the effect of the above-described compound on the expression of integrin in cells other than the platelets based on the expression amount measured above.
IT 289483-69-8, E7820
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surrogate marker for sulfonamide compds. on the expression of integrins for screening of antitumor agents and angiogenesis inhibitors)
RN 289483-69-8 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:884431 CAPLUS <<LOGINID::20080317>>
DN 145:263273
TI Novel concomitant use of sulfonamide compound with anti-cancer agent
IN Owa, Takashi; Ozawa, Yoichi; Semba, Taro; Hata, Naoko
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 96pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2006090931 A1 20060831 WO 2006-JP304219 20060228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 1859797 A1 20071128 EP 2006-715262 20060228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
PRAI JP 2005-55132 A 20050228
WO 2006-JP304219 W 20060228
OS MARPAT 145:263273
AB The invention relates to a pharmaceutical composition and a kit characterized by comprising a sulfonamide compound and a platinum complex compound, a DNA-topoisomerase I inhibitor, a metabolic antagonist, a microtubule inhibitor or an antibiotic in combination and a method of treating cancer and/or a method of inhibiting angiogenesis. For example, the synergic antitumor effect of combination of E 7820 and paclitaxel was in vitro tested.
IT 289483-69-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel concomitant use of sulfonamide compound with anti-cancer agent)
RN 289483-69-8 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:884352 CAPLUS <<LOGINID::20080317>>
DN 145:263272
TI Novel use of sulfonamide compound in combination with angiogenesis

inhibitor

IN Semba, Taro; Hata, Naoko; Ozawa, Yoichi; Owa, Takashi

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 88pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006090928	A1	20060831	WO 2006-JP304208	20060228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1797877	A1	20070620	EP 2005-785820	20050913
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	AU 2006217690	A1	20060831	AU 2006-217690	20060228
	CA 2599301	A1	20060831	CA 2006-2599301	20060228
	EP 1862179	A1	20071205	EP 2006-728638	20060228
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	KR 2007114774	A	20071204	KR 2007-721952	20070921
PRAI	JP 2005-54150	A	20050228		
	US 2004-609452P	P	20040913		
	JP 2005-54475	A	20050228		
	WO 2005-JP17238	W	20050913		
	WO 2006-JP304208	W	20060228		

OS MARPAT 145:263272

AB Disclosed is a pharmaceutical composition and a kit, both comprising the combination of a sulfonamide compound with bevacizumab, and a method for the treatment of cancer and/or a method for the inhibition of angiogenesis. For example, synergic antitumor effect of combination of E 7820 and bevacizumab was in vitro tested.

IT 289483-69-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel use of sulfonamide compound in combination with angiogenesis inhibitor)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:317422 CAPLUS <<LOGINID::20080317>>
DN 144:388497
TI Development of a method to evaluate the sensitivity of tumor cells to sulfonamide containing compounds by gene expressing profiling
IN Owa, Takashi; Yokoi, Akira; Ozawa, Yoichi; Kawai, Takatoshi; Ushijima, Rie
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 1405 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006036025	A1	20060406	WO 2005-JP18574	20050930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1797877	A1	20070620	EP 2005-785820	20050913
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	JP 2004-286259	A	20040930		
	JP 2005-54475	A	20050228		
	JP 2005-54866	A	20050228		
	US 2004-609452P	P	20040913		
	JP 2005-54150	A	20050228		
	WO 2005-JP17238	W	20050913		

AB A method based on gene expressing profiling to evaluate the sensitivity of tumor cells to sulfonamide derivs. has been developed. Five general structures describing substitution group positions and ring structures for

the effector sulfonamide containing compds. are claimed. However, the actual gene expression profiles have been studied by applying one of seven specific sulfonamide derivs. including E7070, E7820, LY186641, LY295501, LY-ASAP, LY573636 and CQS to the tumor cells such as HCT116 and MOLT-4 cells. The genes encoded by 1139 nucleotide sequences have been identified to be responsive to the sulfonamide containing compds. in tumor cells (425 genes up-regulated and 714 genes down-regulated) by the gene expression profiling. These genes with the claimed sequences and their protein products can be used as the index markers for assessing the sulfonamide derivative-sensitivity of the tumor cells. The gene expression level can be determined by quantitating RNA transcript using DNA microarray, RT-PCR or hybridization assay. The translated levels of the genes can be determined by quantitating the protein products using ELISA, RIA or Western blotting.

IT 289483-69-8, E7820
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(development of method to evaluate sensitivity of tumor cells to sulfonamide containing compds. by gene expressing profiling)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1332127 CAPLUS <<LOGINID::20080317>>
DN 144:64366
TI Method for treating or preventing obesity with adipogenesis-inhibiting agents which antagonize fibroblast growth factor signaling
IN Prins, Johannes Bernhard; Hutley, Louise Joyce; Mcgeary, Ross Peter
PA Australia
SO U.S. Pat. Appl. Publ., 145 pp., Cont.-in-part of Appl. No. PCT/AU03/00826.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005282733	A1	20051222	US 2004-21305	20041223
	WO 2004003179	A1	20040108	WO 2003-AU826	20030627

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-392130P P 20020627
WO 2003-AU826 A2 20030627
EP 2004-900050 A 20040107

OS MARPAT 144:64366

AB The invention discloses methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes, i.e., adipogenesis, by antagonizing fibroblast growth factor signaling. These agents may be used to prevent or treat obesity. The antiobesity agents include 6-arylpyrido[2,3-d]pyrimidines and naphthyridines, 2-arylbenzimidazoles, benzofuro[3,2-c]quinolines, pyrimidine derivs., 2,2'-dithiobis(1H-indoles), 4-anilinoquinazolines, 4-anilinoquinolines and cinnolines, 1-oxo-3-aryl-1H-indene carboxylic acid derivs., indolinones, 8-prenylflavonones, tetrahydropyridizines and tetrahydropyridizin-3-ones, sulfonamide-containing heterocyclic compds., etc. Addnl. agents include sugars, oligosaccharides, and carbohydrates such as carrageenans, salts or complexes of sulfated saccharides, and sulfomannans, and RNA binding to FGF-2 or peptides which antagonize FGF-2 binding to its receptor. Thus, inhibition of post-fibroblast growth factor receptor signal transduction was shown to have marked effects on FGF-1-mediated human adipogenesis. Inhibition of protein kinase C, phosphatidylinositol 3-kinase, and phospholipase Cγ all significantly reduced differentiation. MEK and p38 kinase inhibition during preadipocyte replication phase alone significantly reduced subsequent differentiation.

IT 289483-69-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treating or preventing obesity with adipogenesis-inhibiting agents which antagonize fibroblast growth factor signaling)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



L7 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:638738 CAPLUS <<LOGINID::20080317>>
DN 143:146696
TI Differentiation-modulating agents and uses therefor
IN Prins, Johannes Bernhard; Hutley, Louise Joyce; Mcgeary, Ross Peter
PA The University of Queensland, Australia; The Council of the Queensland Institute of Medical Research
SO PCT Int. Appl., 283 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005065686	A1	20050721	WO 2005-AU8	20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	AU 2004-900050	A	20040107		

OS MARPAT 143:146696
AB This invention discloses methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signalling pathway, especially the FGF-1 or FGF-2 signalling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma and lipomatosis.
IT 289483-69-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiobesity differentiation-modulating agents)
RN 289483-69-8 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:260024 CAPLUS <<LOGINID::20080317>>
DN 142:336244
TI Method for producing sulfonamide-containing indole derivatives
IN Hayashi, Kenji; Abe, Taichi; Ozeki, Naoki; Akamatsu, Hiroshi
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026119	A1	20050324	WO 2004-JP12650	20040901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2007037854	A1	20070215	US 2006-571285	20060309
PRAI	JP 2003-318974	A	20030910		
	WO 2004-JP12650	W	20040901		

OS CASREACT 142:336244; MARPAT 142:336244
GI



I

AB Disclosed is a method for producing a compound I [R1 and R2 independently represent a hydrogen atom, a C1-4 alkyl group or the like; R represents ASO2NH; A represents a cyanophenyl group or the like] which is characterized by reacting a compound I (wherein R1 and R2 independently represent a hydrogen atom, a C1-4 alkyl group or the like; R represents NH2) with a compound represented by ASO2Cl (A represents a cyanophenyl group or the like) in a mixed solvent of water and an acetic acid C1-6 alkyl ester in the presence of a base. The title compds. are useful as antitumor agents (no data). Thus, a mixture of 7-amino-3-cyano-4-methyl-1H-indole and 3-cyanobenzenesulfonyl chloride in Me acetate and water containing pyridine was stirred for 2 h 40 min to give, after workup,

N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide.

IT 289483-69-8P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for producing sulfonamide-containing indole derivs. as antitumor agents)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:145031 CAPLUS <<LOGINID::20080317>>

DN 141:235811

TI An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a Xenograft model: possible value of integrin α2 on platelets as a biological marker

AU Semba, Taro; Funahashi, Yasuhiro; Ono, Naoto; Yamamoto, Yuji; Sugi, Naoko Hata; Asada, Makoto; Yoshimatsu, Kentaro; Wakabayashi, Toshiaki

CS Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, Japan

SO Clinical Cancer Research (2004), 10(4), 1430-1438
CODEN: CCREF4; ISSN: 1078-0432

PB American Association for Cancer Research

DT Journal

LA English

AB We reported previously that an angiogenesis inhibitor, E7820, inhibits in vitro tube formation of human umbilical vein endothelial cell through the suppression of integrin α2 expression. Here we describe the antiangiogenic and antitumor effects of E7820 in mice and discuss the feasibility of using platelet integrin α2 expression on platelets as a biol. marker of the efficacy of E7820. Oral administration of E7820 significantly inhibited basic fibroblast growth factor-induced angiogenesis in Matrigel implants and human colon WiDr tumor-induced angiogenesis in a dorsal air sac model. Twice-daily treatment with E7820 clearly inhibited the s.c. tumor growth of seven tumor cell lines derived from human colon, breast, pancreas, and kidney, and completely suppressed the growth of human pancreatic KP-1 and human colon LoVo cell lines. Moreover, E7820 significantly inhibited the growth of KP-1 and human colon

tumor Colo320DM cells orthotopically implanted in the pancreas and cecum, resp. The efficacy of E7820 was comparable in the s.c. and orthotopic transplantation models. Immunohistochem. analyses using anti-CD31 antibody showed that E7820 significantly reduced microvessel d. in orthotopically implanted KP-1 tumor. E7820 reduced integrin α2 expression on a megakaryocytic cell line, Dami cells, induced by phorbol 12-myristate 13-acetate treatment. It also decreased the expression level of integrin α2 on platelets withdrawn from mice bearing s.c. KP-1 tumor at a dosage close to that affording antitumor activity. These data demonstrate that E7820 showed a broad-spectrum antitumor effect in mice through inhibition of angiogenesis and indicate that the decrease of integrin α2 on platelets might serve as a biol. marker for the antitumor efficacy of E7820.

IT 289483-69-8, E7820
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiogenesis inhibitor E7820 showed broad-spectrum antitumor effect tough angiogenesis inhibition and indicate decrease of integrin-2 on platelet might serve as biol. marker for antitumor efficacy of E7820 in mouse xenograft)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:719299 CAPLUS <<LOGINID::20080317>>
DN 139:240339
TI Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
IN Wakabayashi, Toshiaki; Ono, Naoto; Semba, Taro; Haneda, Toru
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003074045	A1	20030912	WO 2003-JP2492	20030304

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003211594	A1	20030916	AU 2003-211594	20030304
EP	1481678	A1	20041201	EP 2003-743594	20030304

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US	2005119303	A1	20050602	US 2004-504676	20040813
PRAI JP	2002-59471	A	20020305		
WO	2003-JP2492	W	20030304		

OS MARPAT 139:240339

GI



I

AB It is intended to provide compns. and kits for treating tumor whereby the angiogenesis inhibitory activity and the antitumor activity of a sulfonamide-containing heterocyclic compound represented by the following formula (I) can be more effectively exerted. By combining with a VEGF inhibitor or an FGF inhibitor, the sulfonamide-containing heterocyclic compound can be effectively employed in treating cancer.

IT 289483-69-8D, E7820, analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitora)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:221508 CAPLUS <<LOGINID::20080317>>
DN 138:231789
TI Heterocyclic sulfonamide/sulfonic ester derivative appetite-stimulating agents and remedies for anorexia
IN Owa, Takashi; Ozawa, Yoichi; Hida, Takayuki; Miyamoto, Norimasa; Nagasu, Takeshi; Okauchi, Tatsuo; Yoshino, Hiroshi; Hata, Naoko; Yoshimatsu, Kentaro; Koyanagi, Nozomu; Kito, Kyosuke
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003022272	A1	20030320	WO 2002-JP9031	20020905
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002332298	A1	20030324	AU 2002-332298	20020905
	EP 1433479	A1	20040630	EP 2002-767898	20020905
	EP 1433479	B1	20071205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	AT 380028	T	20071215	AT 2002-767898	20020905
	US 2004242628	A1	20041202	US 2004-488825	20040305
	US 7015241	B2	20060321		
PRAI	JP 2001-269481	A	20010905		
	WO 2002-JP9031	W	20020905		

OS MARPAT 138:231789
GI



I

AB The present invention relates to appetite-stimulating agents containing as the active ingredient sulfonamide or sulfonic ester derivs. represented by the general formula I, pharmacol. acceptable salts thereof, or hydrates of both; wherein A is an optionally substituted mono- or bi-cyclic aromatic ring; B is an optionally substituted six-membered unsatd. hydrocarbon ring or an unsatd. six-membered heterocycle containing one nitrogen atom; C is an optionally substituted five-membered heterocycle containing one or two nitrogen atoms; W is a single bond or CH:CH; X is N(R1) or oxygen; Y is carbon or nitrogen; Z is N(R2) or nitrogen; and R1 and R2 are each independently hydrogen or lower alkyl. Thus, N-(3-Chloro-1H-indole-7-yl)-4-cyanobenzenesulfonamide showed good body weight and food intake increase in mice.

IT 289483-69-8, 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic sulfonamide/sulfonic ester derivative appetite-stimulating agents for anorexia)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:221507 CAPLUS <<LOGINID::20080317>>

DN 138:248504

TI Lymphocytic activation inhibitor and remedial agent for autoimmune disease

IN Hanada, Takahisa; Yamauchi, Toshihiko; Chiba, Kenichi; Owa, Takashi; Hida, Takayuki; Miyamoto, Norimasa

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003022271	A1	20030320	WO 2002-JP9030	20020905
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002335346	A1	20030324	AU 2002-335346	20020905
	TW 589181	B	20040601	TW 2002-91120346	20020905
	EP 1430894	A1	20040623	EP 2002-798032	20020905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1551766	A	20041201	CN 2002-817484	20020905
	US 2004235866	A1	20041125	US 2004-488654	20040304
PRAI	JP 2001-269480	A	20010905		
	WO 2002-JP9030	W	20020905		

OS MARPAT 138:248504

GI



I

AB A lymphocytic activation inhibitor and a remedial agent for autoimmune diseases which each comprises as an active ingredient a sulfonamide derivative or sulfonic ester derivative represented by the general formula (I): I [wherein ring A means an optionally substituted, mono- or bicyclic aromatic ring; ring B means an optionally substituted, 6-membered, cyclic unsatd. hydrocarbon or an unsatd. 6-membered heterocycle containing one nitrogen atom; ring C means an optionally substituted 5-membered heterocycle containing one or two nitrogen atoms; W means a single bond or -CH=CH-; X means -N(R1)- or oxygen; Y means carbon or nitrogen; Z means -N(R2)- or nitrogen; and R1 and R2 are the same or different and each means hydrogen or lower alkyl], a pharmacol. acceptable salt thereof, or a hydrate of any of these.

IT 289483-69-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(a sulfonamide derivative or sulfonic ester derivative as lymphocytic

activation inhibitor and remedial agent for autoimmune disease)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:859508 CAPLUS <<LOGINID::20080317>>

DN 138:378719

TI Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin α2 subunit on endothelium

AU Funahashi, Yasuhiro; Sugi, Naoko Hata; Semba, Taro; Yamamoto, Yuji; Hamaoka, Shinichi; Tsukahara-Tamai, Naoko; Ozawa, Yoichi; Tsuruoka, Akihiko; Nara, Kazumasa; Takahashi, Keiko; Okabe, Tadashi; Kamata, Junichi; Owa, Takashi; Ueda, Norihiro; Haneda, Toru; Yonaga, Masahiro; Yoshimatsu, Kentaro; Wakabayashi, Toshiaki

CS Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, 300-2635, Japan

SO Cancer Research (2002), 62(21), 6116-6123
CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

AB In the process of angiogenesis, endothelial adhesion mols. play a significant role in vascular morphogenesis, in coordination with angiogenic factor signaling. Here we report that a novel angiogenesis inhibitor, E7820 (an aromatic sulfonamide derivative), inhibited in vitro proliferation and tube formation of human umbilical vascular endothelial cell (HUVEC). E7820 decreased integrin α2, 3, 5, and β1 in confluent culture of HUVEC, and integrin α2 was initially suppressed in mRNA level, followed by decrement of integrins α3, 5, and β1. The inhibition of integrin α2 expression in HUVEC showed dose dependence but did not alter the level of CD31. Up-regulation of integrin α2 by phorbol 12-myristate 13-acetate abrogated the inhibitory effect of E7820 on tube formation within type I collagen gel, whereas addition of antibody against integrin α2 canceled the phorbol 12-myristate 13-acetate effect. These results suggest that E7820 inhibited tube formation through the suppression of integrin α2. Oral administration of E7820 remarkably resulted in inhibition of tumor-induced angiogenesis in mouse dorsal air sac model, and tumor growth of human colorectal tumor cell lines (WiDr and LoVo) was inhibited in

xenotransplanted model in mice. This is the first time that a small mol. has been shown to modulate integrins, and this finding may provide the basis for a new approach to antiangiogenic therapy through the suppression of integrin α2 on endothelium.

IT 289483-69-8, E 7820
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E7820 suppresses integrin α2 on endothelium and has antiangiogenic and antitumor activity)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:657984 CAPLUS <<LOGINID::20080317>>
DN 137:179847
TI Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression
IN Ono, Naoto; Senba, Taro; Hata, Naoko; Funahashi, Yasuhiro; Wakabayashi, Toshiaki
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002066073	A1	20020829	WO 2002-JP1562	20020221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438427	A1	20020829	CA 2002-2438427	20020221

	AU 2002233677	A1	20020904	AU 2002-233677	20020221
	EP 1362601	A1	20031119	EP 2002-700679	20020221
	EP 1362601	B1	20070103		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1620313	A	20050525	CN 2002-808637	20020221
	EP 1742052	A1	20070110	EP 2006-13455	20020221
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	AT 350660	T	20070115	AT 2002-700679	20020221
	CN 101025419	A	20070829	CN 2007-10087817	20020221
	ES 2280502	T3	20070916	ES 2002-700679	20020221
	US 2004132783	A1	20040708	US 2004-468615	20040120
	US 7122318	B2	20061017		
	HK 1059038	A1	20070323	HK 2004-101904	20040316
PRAI	JP 2001-44646	A	20010221		
	CN 2002-808637	A3	20020221		
	EP 2002-700679	A3	20020221		
	WO 2002-JP1562	W	20020221		

OS MARPAT 137:179847

AB A method of examining the effect of a drug on the expression of an integrin which comprises the step of measuring the expression dose of the integrin in platelets of a patients to whom the drug has been administered and the step of evaluating the effect of the drug on the expression of the integrin in cells other than platelets on the basis of the expression dose thus measured.

IT 289483-69-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:581738 CAPLUS <<LOGINID::20080317>>
DN 135:175421
TI Integrin expression inhibitors

IN Wakabayashi, Toshiaki; Funahashi, Yasuhiro; Hata, Naoko; Semba, Taro; Yamamoto, Yuji; Haneda, Toru; Owa, Takashi; Tsuruoka, Akihiko; Kamata, Junichi; Okabe, Tadashi; Takahashi, Keiko; Nara, Kazumasa; Hamaoka, Shinichi; Ueda, Norihiro

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 153 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001056607	A1	20010809	WO 2001-JP713	20010201
	W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2399001	A1	20010809	CA 2001-2399001	20010201
	AU 2001028867	A	20010814	AU 2001-28867	20010201
	AU 781506	B2	20050526		
	EP 1258252	A1	20021120	EP 2001-948941	20010201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	HU 2003000544	A2	20030728	HU 2003-544	20010201
	HU 2003000544	A3	20050329		
	NZ 520299	A	20040528	NZ 2001-520299	20010201
	RU 2240826	C2	20041127	RU 2002-123580	20010201
	JP 4039856	B2	20080130	JP 2001-556505	20010201
	US 2004018192	A1	20040129	US 2002-181562	20020718
	MX 2002PA07249	A	20021209	MX 2002-PA7249	20020725
	KR 767000	B1	20071015	KR 2002-709945	20020801
	NO 2002003688	A	20021003	NO 2002-3688	20020802
	US 2005176712	A1	20050811	US 2005-97218	20050404
	KR 767002	B1	20071015	KR 2007-701761	20070124
PRAI	JP 2000-26080	A	20000203		
	JP 2000-402084	A	20001228		
	WO 2001-JP713	W	20010201		
	US 2002-181562	A1	20020718		
	KR 2002-709945	A3	20020801		

OS MARPAT 135:175421

AB Integrin expression inhibitors and remedies for arteriosclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinitis or inflammatory diseases, anticoagulant agents and cancerous metastasis inhibitors based on the integrin inhibitory effect. Namely, integrin expression inhibitors containing as the active ingredient sulfonamide compds. represented by the following general formula BKSO2N(R1)ZR, pharmacol. acceptable salts thereof or hydrates of the same wherein B represents optionally substituted C6-10 aryl or 6- to 10-membered heteroaryl wherein the ring may be partly saturated; K represents a single bond, -CH=CH- or -(CR4bR5b)mb- (wherein R4b and R5b may be the same or different and each represents hydrogen or C1-4 alkyl; and mb represents an integer of 1 or 2); R1 represents hydrogen or C1-6 alkyl; Z represents a single bond or CO-NH-; and R represents optionally substituted C6-10 aryl or 6- to 10-membered heteroaryl wherein the ring may be partly saturated

IT 289483-69-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(integrin expression inhibitors for medical uses)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:608721 CAPLUS <<LOGINID::20080317>>
DN 133:193071
TI Preparation of sulfonamide-containing indole derivatives as inhibitors of neovascularization and tumor
IN Haneda, Toru; Tsuruoka, Akihiko; Kamata, Junichi; Okabe, Tadashi; Takahashi, Keiko; Nara, Kazumasa; Hamaoka, Shinichi; Ueda, Norihiro; Ohwa, Takashi; Wakabayashi, Toshiaki; Funahashi, Yasuhiro; Semba, Taro; Hata, Naoko; Yamamoto, Yuji; Ozawa, Yoichi; Tsukahara, Naoko
PA Eisai Co., Ltd., Japan; et al.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050395	A1	20000831	WO 2000-JP1071	20000224
	W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2000247949	A	20000912	JP 1999-49870	19990226
	CA 2327253	A1	20000831	CA 2000-2327253	20000224
	CA 2327253	C	20071016		
	EP 1074542	A1	20010207	EP 2000-905321	20000224
	EP 1074542	B1	20060503		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	HU 2001001434	A2	20010928	HU 2001-1434	20000224
	HU 2001001434	A3	20011029		
	RU 2208607	C2	20030720	RU 2000-129508	20000224
	AU 766936	B2	20031023	AU 2000-26916	20000224
	NZ 507464	A	20031031	NZ 2000-507464	20000224
	CN 1132814	B	20031231	CN 2000-800229	20000224
	AT 325094	T	20060615	AT 2000-905321	20000224
	PT 1074542	T	20060731	PT 2000-905321	20000224
	ES 2259997	T3	20061101	ES 2000-905321	20000224
	JP 3866041	B2	20070110	JP 2000-600978	20000224

	US 6469043	B1	20021022	US 2000-647215	20000928
	MX 2000PA10243	A	20010410	MX 2000-PA10243	20001019
	NO 2000005357	A	20001222	NO 2000-5357	20001024
	NO 317299	B1	20041004		
	US 2002128480	A1	20020912	US 2002-98420	20020318
	US 6673787	B2	20040106		
	US 2002128483	A1	20020912	US 2002-98421	20020318
	US 6638964	B2	20031028		
	JP 2006312652	A	20061116	JP 2006-226414	20060823
PRAI	JP 1999-49870	A	19990226		
	JP 2000-600978	A3	20000224		
	WO 2000-JP1071	W	20000224		
	US 2000-647215	A3	20000928		

OS MARPAT 133:193071

GI



I



II

AB The title compds. I [R1 represents hydrogen, etc.; R2 and R3 are the same or different and each represents hydrogen, etc.; R4 represents hydrogen or lower (C1-4) alkyl; and the ring A represents cyanophenyl, etc., provided that the following cases are excluded: the one where R1, R2 and R3 are all hydrogen atoms; the one where R2 and R3 are both hydrogen atoms; and the one where the ring A is an aminosulfonylphenyl group and R1 and R2 are both halogen atoms; and provided that when the ring A is a cyanophenyl, 2-amino-5-pyridyl or 2-halogeno-5-pyridyl group and R1 is a cyano group or a halogen atom, then at least one of R2 and R3 is not hydrogen] are prepared The title compound II in vitro showed IC50 of 10 μg/mL against mouse B16 melanoma cells.

IT 289483-69-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide-containing indole derivs. as inhibitors of neovascularization and tumor)

RN 289483-69-8 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- (CA INDEX

NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT